Correction to: Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study ’’ by Subbiah et al. Thyroid 2024;34(1):26–40; doi: 10.1089/thy.2023.0363

Thyroid ®, Ahead of Print.
Source: Thyroid - Category: Endocrinology Source Type: research